US2020222550A1PendingUtilityA1

Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f

Assignee: MERCK SHARP & DOHMEPriority: Jan 31, 2017Filed: Jan 30, 2018Published: Jul 16, 2020
Est. expiryJan 31, 2037(~10.5 yrs left)· nominal 20-yr term from priority
G01N 33/56944C07K 14/34A61K 47/646A61K 47/6415A61K 2039/6037A61K 39/092G01N 2333/345G01N 2333/315A61K 47/36
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.

Claims

exact text as granted — not AI-modified
1 . A method for the production of a polysaccharide-protein conjugate comprising  Streptococcus pneumoniae  serotype 19F capsular polysaccharide covalently linked to a carrier protein from a mixture comprising polysaccharide-protein conjugate and free polysaccharide, the method comprising the steps of:
 a) incubating said mixture for a minimum of 6 hours at a temperature ranging from 2-30° C. in a buffer having a pH in the range of 5.0 to 9.0; and   b) performing size separation under conditions that allow removal of free polysaccharide.   
     
     
         2 . The method of  claim 1 , wherein said size separation uses a nominal molecular weight cut off membrane of from 100 to 500 kDa whereby the polysaccharide-protein conjugate is retained in the retentate. 
     
     
         3 . The method of  claim 1 , further comprising
 c) collecting the polysaccharide-protein conjugate.   
     
     
         4 . The method of  claim 1 , wherein the carrier protein is CRM 197 . 
     
     
         5 . The method of  claim 2 , wherein the retained polysaccharide-protein conjugate has an average molecular weight of 600 kDa or more. 
     
     
         6 . The method of  claim 5  wherein the polysaccharide-protein conjugate has an average molecular weight of 1000 kDa or more. 
     
     
         7 . The method of  claim 1 , wherein said buffer is selected from a phosphate buffer, histidine, and TRIS. 
     
     
         8 . The method of  claim 1 , wherein said buffer has a pH in the range of pH 5.8 to 7.0. 
     
     
         9 . The method of  claim 8 , wherein said buffer has a pH of 7.0. 
     
     
         10 . The method of  claim 1 , wherein the incubation temperature is in the range of 4-25° C. 
     
     
         11 . The method of  claim 1 , wherein said size separation is by size-exclusion chromatography, bind/elute chromatography, or wide-pore ultrafiltration. 
     
     
         12 . The method of  claim 11 , wherein said size separation is by wide-pore ultrafiltration with a membrane having a MWCO of 100 kDa to 300 kDa. 
     
     
         13 . The method of  claim 1 , wherein the incubation is for at least 12 hours. 
     
     
         14 . The method of  claim 13 , wherein the incubation is for 108 to 132 hours. 
     
     
         15 . The method of  claims 1 , further comprising formulating the polysaccharide-protein conjugate with one or more additional polysaccharide-protein conjugates from a different serotype. 
     
     
         16 . The method of  claim 15 , further comprising formulating with an adjuvant. 
     
     
         17 . A serotype 19F polysaccharide protein conjugate produced by the method of  claims 1 . 
     
     
         18 . A method for measuring dose and/or potency in a pneumococcal conjugate vaccine manufacturing lot comprising performing an immunoassay for serotype 19F polysaccharide protein conjugate in said manufacturing lot using the 19F conjugate of  claim 17  as a reference standard.

Join the waitlist — get patent alerts

Track US2020222550A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.